ArticleBMC microbiology2025
Characterization of urinary Escherichia coli isolates in HIV-seropositive women with asymptomatic bacteriuria in Western Ghana.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAsymptomatic bacteriuria (ASB), a precursor of urinary tract infection (UTI), is highly prevalent among people living with HIV (PLHIV). In this study, we characterized urinary Escherichia coli isolated from PLHIV with asymptomatic bacteriuria.
methodsUrine samples from women living with HIV (WLHIV) were cultured, and bacteria isolates were identified using MALDI TOF biotyper. Antimicrobial susceptibility test was performed on isolates and genes encoding virulence factors and integrases were screened using Multiplex PCR and gel imaging. Patients' predictor variables like WHO disease staging, Highly Active Antiretroviral Therapy (HAART) duration and viral load were extracted from patient folders using a structured questionnaire.
resultsThe mean age of our 400 participants was 43.5 ± 12 years, 78.5% had viral loads < 1000 copies/ml, 53.8% had been on HAART for 1-5 years and 62.5% were classified as having WHO stage III disease. 85 of 400 (21.2%) urine samples cultured positive, and the most prevalent organism was E. coli (69.4%, 59/85), all being multidrug-resistant. None of the patients' predictor variables reached statistical significance; WHO disease stage (OR = 0.953, 95%CI = 0.683-1.330, p = 0.777), age (OR = 0.1.207, 95%CI = 0.971-1.499, p = 0.090), HAART duration (OR = 1.233, 95%CI = 0.923-1.648, p = 0.156, and viral load (OR = 0.915, 95%CI = 0.774-1.082, p = 0.298). Lower resistance rates were recorded for meropenem and fosfomycin (1.7%), nitrofurantoin (6.8%, 4/59) and amikacin (8.5%, 5/59). The most common virulence genes identified were chuA (66.1%, 39/59), papC (57.6%, 34/59) and cnf1 (50.8%, 30/59). Integrons identified were intI 42% (25/59) and intII 20% (12/59).
conclusionASB is common in our HIV- seropositive participants, indicating that WLHIV are at a higher risk of developing complications from UTIs. Though fosfomycin may be useful in managing UTIs in this population group, the high prevalence of multidrug-resistant, E. coli harbouring diverse virulence genes, warrants surveillance of ASB among this vulnerable group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.